Abstract
Prognostic information regarding the risk of postoperative tumor recurrence defined by a profile of serological, morphological and/or molecular markers can have potential value particularly for patients with colorectal carcinoma (CRC) of UICC stage II/III, who may benefit from adjuvant chemotherapy after surgery.
A retrospective study of 783 patients with CRC (UICC I–III) including a subgroup analysis of 116 subjects was conducted to determine preoperative serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19–9, and p53 serum levels. In addition, protein and gene expression of p53, CEA, and adenomatous polyposis coli (APC) was assessed in the tumors of those patients. The values of all serological, morphological and molecular parameters were correlated with clinicopathological characteristics for their predictive value of tumor recurrence over a mean follow-up period of 32 ± 6.2 months.
Serum CEA but not CA 19–9 or p53 was a significant prognostic factor for disease free survival along with UICC and T/N-stage. When comparing elevated CEA, CA 19–9, and p53 serum levels with expression of the markers in the tumors, their overall expression was found to be 61.3 % in the serum versus 93.5 % in the tumor in the analyzed patients (n = 116). In particular, all patients in UICC stage I-III who demonstrated at least three elevated markers (CEA/CA19-9/p53) in serum and/or in the tumor presented with tumor recurrence/metastases.
Overall increased p53, CEA, and CA 19–9 serum levels and their marker expression in the tumor may be used at the time of primary tumor removal for defining patients at risk for tumor recurrence.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Wang WS, Lin JK, Chiou TJ et al (2002) CA 19-9 as the most significant prognostic indicator of metastatic colorectal cancer. Hepatogastroenterology 49: 160–164
Allende T, Garcia Muniz JL, Vizoso F et al (2001) Preoperative serum levels of the carcinoembryonic antigen (CEA) and prognosis in colorectal cancer. Rev Esp Med Nucl 20(5): 358–364
Allegra CJ, Paik S, Colangelo LH et al (2003) Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21(2): 241–250
Watanabe T, Wu TT, Catalano PJ et al (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344(16): 1196–1206
Chen CC, Yang SH, Lin JK et al (2005) Is it reasonable to add preoperative serum level of CEA and CA 19-9 to staging for colorectal cancer? J Surg Res 124(2): 169–174
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Medizin Verlag Heidelberg
About this paper
Cite this paper
Gasser, M. et al. (2007). Vergleichende Analyse praediktiver Biomarker für therapeutische Strategien beim kolorektalen Karzinom. In: Steinau, H.U., Schackert, H.K., Bauer, H. (eds) Chirurgisches Forum 2007. Deutsche Gesellschaft für Chirurgie, vol 36. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-71123-0_45
Download citation
DOI: https://doi.org/10.1007/978-3-540-71123-0_45
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-71122-3
Online ISBN: 978-3-540-71123-0
eBook Packages: Medicine (German Language)